Santhera Pharmaceuticals (Schweiz) AG

Address

About the company Santhera Pharmaceuticals (Schweiz) AG

Santhera Pharmaceuticals (Schweiz) AG, based in Pratteln, is a company in Switzerland. Santhera Pharmaceuticals (Schweiz) AG is active according to the commercial register. The company with the UID number CHE-112.001.828 was founded on 09/14/2004. In the database of the IGE (Swiss Federal Institute for Intellectual Property) there are currently several trademarks or applications for the company Santhera Pharmaceuticals (Schweiz) AG.

Company description and purpose of company Santhera Pharmaceuticals (Schweiz) AG

Santhera Pharmaceuticals (SWX: SANN) is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of severe neuromuscular diseases. Santhera's vision is to become a leading specialty pharmaceutical company offering therapies for a number of indications in this area of ​​high unmet medical need which includes many orphan indications with no current therapy. Santhera currently has five clinical-stage development programs, three of which are investigating its lead compound, SNT-MC17 (INN: idebenone), in the treatment of Friedreich's Ataxia (FRDA), Duchenne Muscular Dystrophy (DMD) and Leber's Hereditary Optic Neuropathy ( LHON). Another clinical program is investigating JP- 1730 (INN: fipamezole) for the treatment of Dyskinesia in Parkinson's Disease (DPD) in cooperation with Juvantia, the compound's owner. The fifth program comprises SNT-317 (INN: omigapil) in Congenital Muscular Dystrophies (CMD), a compound in-licensed from Novartis. Santhera's first product, SNT-MC17 (INN: idebenone) has received a marketing approval with conditions from Health Canada to treat Friedreich's Ataxia and will be marketed under its brand name Catena. The product is also under review by health authorities in the EU and in Switzerland for the same indication, while in the United States a pivotal phase III trial is recruiting patients. SNT-MC17 has recently shown efficacy as a potential treatment in DMD, the compound's second indication.

Translated by google.com

The company Santhera Pharmaceuticals (Schweiz) AG on Hohenrainstrasse 24 in 4133 Pratteln with the phone number 061 906 89 50 is listed on Yellowpages.swiss. Latitude and longitude coordinates for Santhera Pharmaceuticals (Schweiz) AG are: 47.5258916 and 7.6951285. The unique identification number of this portrait is CHE-112.001.828.

The company Santhera Pharmaceuticals (Schweiz) AG is listed in the branch Medicine - Hospital - Doctor. other products or services according to the company's purpose.

---

Data Source: HELP.CH your e-guide ®

Which companies are available at the same address? In addition to Santhera Pharmaceuticals (Schweiz) AG, there are other active companies at the same address Hohenrainstrasse 24, 4133 Pratteln. This includes the companies Editorial Media Group AG| PRESTIGE Finance AG| Cryptologix AG.